Curated Wealth Partners LLC Buys New Position in DexCom, Inc. $DXCM

Curated Wealth Partners LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,112 shares of the medical device company’s stock, valued at approximately $359,000.

A number of other hedge funds have also recently modified their holdings of the business. Sagespring Wealth Partners LLC grew its holdings in DexCom by 4.4% during the second quarter. Sagespring Wealth Partners LLC now owns 11,017 shares of the medical device company’s stock valued at $962,000 after purchasing an additional 465 shares during the period. TD Asset Management Inc grew its holdings in DexCom by 25.2% during the second quarter. TD Asset Management Inc now owns 276,028 shares of the medical device company’s stock valued at $24,094,000 after purchasing an additional 55,644 shares during the period. Moran Wealth Management LLC bought a new position in shares of DexCom during the 2nd quarter valued at approximately $2,464,000. Sequoia Financial Advisors LLC grew its stake in shares of DexCom by 13.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,713 shares of the medical device company’s stock valued at $761,000 after acquiring an additional 1,049 shares during the period. Finally, Yousif Capital Management LLC grew its stake in shares of DexCom by 0.9% during the 2nd quarter. Yousif Capital Management LLC now owns 53,429 shares of the medical device company’s stock valued at $4,664,000 after acquiring an additional 484 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director directly owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock worth $564,733 in the last 90 days. 0.32% of the stock is currently owned by insiders.

DexCom Price Performance

Shares of DexCom stock opened at $66.21 on Wednesday. The stock has a 50 day moving average of $74.01 and a 200 day moving average of $77.62. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The firm has a market cap of $25.96 billion, a PE ratio of 45.98, a PEG ratio of 1.37 and a beta of 1.47. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on DXCM shares. Raymond James Financial upped their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 31st. William Blair raised shares of DexCom to a “strong-buy” rating in a report on Thursday, July 31st. Citigroup dropped their target price on shares of DexCom from $105.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Robert W. Baird dropped their target price on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a report on Friday, September 26th. Finally, Oppenheimer lowered DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.42.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.